Drug intelligence / Profile preview

OPL-0401

Development stage: Phase 2
Lead developer: Valo Health
Modality: Small Molecules
Administration: Oral

Overview

OPL-0401 is an investigational small molecule drug that acts as a Rho kinase (ROCK) 1 and 2 inhibitor. It was developed as a potential first-in-class oral treatment for diabetic retinopathy, targeting patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR). The drug demonstrated a favorable safety profile in clinical trials but did not meet its primary or secondary efficacy endpoints in Phase 2 studies. OPL-0401 was originally licensed from Sanofi and further developed by Valo Health, which has since suspended development and is seeking a partner to continue the program[3][6][8].

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on OPL-0401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPL-0401.

Explore the full profile